Trial Profile
Randomised phase II window study of short-term preoperative treatment with the PI3K inhibitor GDC-0941 plus Anastrozole versus Anastrozole alone in patients with ER-positive primary breast cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 28 Mar 2023
Price :
$35
*
At a glance
- Drugs Anastrozole (Primary) ; Pictrelisib (Primary)
- Indications Early breast cancer; HER2 negative breast cancer
- Focus Biomarker; Therapeutic Use
- Acronyms OPPORTUNE
- 28 Jan 2016 Status changed from recruiting to completed according to United Kingdom Clinical Research Network.
- 12 Dec 2015 Interim results (n=70) presented at the 38th Annual San Antonio Breast Cancer Symposium.
- 11 Oct 2015 Accrual to date is 118% according to the United Kingdom Clinical Research Network record.